Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00918645 · ClinicalTrials.gov registry record · NA

Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis

A NA study, sponsored by University of California, Davis.

Terminated
Registry status
NA
Development phase
13
Enrollment target

NCT00918645: Clinical Trial NA study, sponsored by University of California, Davis.

NCT00918645 is a NA study that was terminated before completion, run by University of California, Davis. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00918645, a NA study, was terminated before completion, sponsored by University of California, Davis.

TERMINATED
Registry status
NA
Development phase
13 participants
Enrollment target

Study Summary

RATIONALE: Diagnostic procedures, such as radionuclide imaging using calcium-41 (41Ca) chloride aqueous solution, may help predict progressive disease in patients with prostate cancer and bone metastasis. PURPOSE: This clinical trial is studying how well calcium-41 (41Ca) chloride aqueous solution works in diagnosing patients with prostate cancer and bone metastasis.

Primary Outcome

Pre-dose specimens will be provided immediately prior to dose administration. Day 1 specimens shall be collected by the subjects 6 hours after dosing (at home); all subsequent urine specimens may be collected at any time during the day and blood specimens should be taken at the same time of day, if feasible (e.g., morning fasted).

Interventions

  • DRUG 41 Ca

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2009-09
Est. Completion 2013-06
Phase NA
University of California, Davis

657 total trials

Why NCT00918645 stopped before completion

NCT00918645 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which 41 Ca is the first listed.

NCT00918645 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00918645 about?

NCT00918645 is a clinical study titled "Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis". RATIONALE: Diagnostic procedures, such as radionuclide imaging using calcium-41 (41Ca) chloride aqueous solution, may help predict progressive disease in patients with prostate cancer and bone metastasis. PURPOSE: This clinical trial is studying how well calcium-41 (41Ca) chloride aqueous solution ...

What is the current status of trial NCT00918645?

This trial is currently terminated. It is a NA study. The enrollment target is 13 participants. The study started on 2009-09. Estimated completion is 2013-06.

What interventions are being tested in trial NCT00918645?

The interventions under investigation include: 41 Ca (DRUG).

Who is sponsoring clinical trial NCT00918645?

This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00918645's enrollment target sits among peer trials

13 1911th of 2000 higher than 88 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03125655 · 13 participants

    Regulation of Inflammatory Genes in Psoriasis

  • NCT03774446 · 13 participants · Phase 2

    Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

  • NCT03830151 · 13 participants · Phase 1

    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

  • NCT04573231 · 13 participants · Phase 2

    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00918645, the US trial registry maintained by the National Library of Medicine. NCT00918645 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.